Nutrition Modulation of Cardiotoxicity in Breast Cancer: A Scoping Review
- PMID: 39519610
- PMCID: PMC11547447
- DOI: 10.3390/nu16213777
Nutrition Modulation of Cardiotoxicity in Breast Cancer: A Scoping Review
Abstract
Background/objectives: Advancements in breast cancer therapeutics, such as anthracyclines, are improving cancer survival rates but can have side effects that limit their use. Cardiotoxicity, defined as damage to the heart caused by cancer therapeutics, is characterised by a significant reduction in left ventricular ejection fraction (LVEF) and symptoms of cardiac dysfunction. Multiple oral supplements exist with antioxidant and anti-inflammatory properties that have the potential to lower cardiotoxicity risk and ameliorate the complications associated with left ventricular dysfunction. In this review, we evaluate the current status of using nutritional interventions to modulate cardiotoxicity.
Methods: We used specific keywords to search for articles that met our predetermined inclusion and exclusion criteria to review the evidence and provide insights for future research.
Results: Seven studies were identified as eligible for this review: six focused on oral supplementation strategies in breast cancer patients undergoing chemotherapy, and one focused on nutritional counselling and adherence to the Mediterranean diet in breast cancer survivors' post-treatment. There was a significantly attenuated reduction in LVEF in five studies that monitored cardiometabolic health, and there were significant improvements in blood serum levels of cardiac biomarkers across all studies.
Conclusions: Current evidence suggests that appropriate nutritional interventions, alongside chemotherapy, can modulate the risk of cardiotoxic side effects. This highlights the potential of oral antioxidant supplementation and Mediterranean diet counselling to decrease tertiary cancer therapy costs associated with cardiovascular complications.
Keywords: LVEF; antioxidant; breast cancer; cardiotoxicity; nutrition.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.Clin Transl Oncol. 2017 Jan;19(1):91-104. doi: 10.1007/s12094-016-1508-y. Epub 2016 Apr 21. Clin Transl Oncol. 2017. PMID: 27101413 Free PMC article.
-
Utility of routine pretreatment evaluation of left ventricular ejection fraction in breast cancer patients receiving anthracyclines.Breast J. 2019 Jan;25(1):62-68. doi: 10.1111/tbj.13182. Epub 2018 Dec 27. Breast J. 2019. PMID: 30592128
-
Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction.J Am Heart Assoc. 2018 Aug 7;7(15):e008637. doi: 10.1161/JAHA.118.008637. J Am Heart Assoc. 2018. PMID: 30371238 Free PMC article.
-
[Cardiotoxicity as undesired side effect in the treatment of breast cancer].Postepy Hig Med Dosw (Online). 2014 May 8;68:483-97. doi: 10.5604/17322693.1101581. Postepy Hig Med Dosw (Online). 2014. PMID: 24864100 Review. Polish.
-
Cancer and cardiovascular disease: the use of novel echocardiography measures to predict subsequent cardiotoxicity in breast cancer treated with anthracyclines and trastuzumab.Curr Heart Fail Rep. 2014 Dec;11(4):366-73. doi: 10.1007/s11897-014-0214-8. Curr Heart Fail Rep. 2014. PMID: 25079445 Free PMC article. Review.
Cited by
-
Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients.J Cardiovasc Dev Dis. 2025 Jun 4;12(6):212. doi: 10.3390/jcdd12060212. J Cardiovasc Dev Dis. 2025. PMID: 40558647 Free PMC article. Review.
-
Cardiotoxicity in Elderly Breast Cancer Patients.Cancers (Basel). 2025 Jun 30;17(13):2198. doi: 10.3390/cancers17132198. Cancers (Basel). 2025. PMID: 40647496 Free PMC article. Review.
-
Prognostic and immunological landscape of DDX17 in pan-cancer analysis: a comprehensive study.Discov Oncol. 2025 Jun 17;16(1):1132. doi: 10.1007/s12672-025-02955-9. Discov Oncol. 2025. PMID: 40526173 Free PMC article.
-
Anticancer Potential of Prebiotics: Targeting Estrogen Receptors and PI3K/AKT/mTOR in Breast Cancer.Biomedicines. 2025 Apr 18;13(4):990. doi: 10.3390/biomedicines13040990. Biomedicines. 2025. PMID: 40299687 Free PMC article. Review.
-
Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment.Life (Basel). 2025 Mar 15;15(3):471. doi: 10.3390/life15030471. Life (Basel). 2025. PMID: 40141815 Free PMC article. Review.
References
-
- Breast Cancer UK. 2022. Facts and Figures. Breast Cancer UK. [(accessed on 19 July 2024)]. Available online: https://www.breastcanceruk.org.uk/about-breast-cancer/facts-figures-and-...
-
- Breast Cancer Research Foundation Breast Cancer Statistics And Resources. Breast Cancer Research Foundation. 2016. [(accessed on 19 July 2024)]. Available online: https://www.bcrf.org/breast-cancer-statistics-and-resources/
-
- World Cancer Research Fund International. (n.d.) Cancer Survival Statistics. WCRF International. [(accessed on 19 July 2024)]. Available online: https://www.wcrf.org/cancer-trends/cancer-survival-statistics/
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous